Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019002612) SYNBIOTIC COMPOSITION FOR PREVENTING METABOLIC DISORDERS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1 A nutritional composition comprising a combination of Bifidobacterium breve and non-digestible oligosaccharides for use in preventing and/or reducing the risk of occurrence of hypercholesterolemia and/or plasma-cholesterol associated atherosclerosis later in life in a human subject by administration of the nutritional composition to the human subject early in life.

2 The nutritional composition for use according to claim 1 wherein early in life is when the human subject has an age of 0 to 36 months, more preferably 0 to 12 months.

3 The nutritional composition for use according to any of the preceding claims wherein later in life is when the human subject has an age above 5 years, more preferably above 18 years.

4 The nutritional composition for use according to any of the preceding claims wherein said human subject is exposed to or raised in an obesogenic environment and/or consumes after infancy a Western Style Diet that is increased in fat and is increased in saturated fatty acids, with the fat providing more than 35 % of the total calories of the diet, and with the saturated fatty acids providing more than 10 % of the total calories of the diet.

5 The nutritional composition for use according to any of the preceding claims wherein said human subject is an at risk infant [selected from the group consisting of a preterm infant, a small for gestational age infant, a large for gestational age infant, an infant born form an overweight or obese mother, an infant born from a mother suffering from diabetes type 2 or gestational diabetes, an infant born by C-section and an infant that is treated or has been treated with antibiotics.

6 The nutritional composition for use according to any of the preceding claims, wherein the Bifidobacterium breve is Bifidobacterium breve M-16V.

7 The nutritional composition for use according to any of the preceding claims, wherein the non- digestible oligosaccharides are selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides and a combination thereof.

8 The nutritional composition for use according to any of the preceding claims wherein the nutritional composition is an infant formula or follow on formula or young child formula, more preferably an infant formula or follow on formula.

9 The nutritional composition for use according to any of the preceding claims wherein the nutritional composition comprises 104 to 1012 cfu Bifidobacterium breve per gram dry weight of the nutritional composition and 0.25 to 20 wt% non-digestible oligosaccharides based on dry weight of the nutritional composition.

The nutritional composition for use according to any of the preceding claims wherein the nutritional composition comprises 104 to 1012 cfu Bifidobacterium breve per gram dry weight of the nutritional composition and 0.25 to 20 wt% of non-digestible oligosaccharides selected from the group consisting of galacto-oligosaccharides and fructo-oligosaccharides and mixtures thereof, based on dry weight of the nutritional composition.

Use of a combination of Bifidobacterium breve and non-digestible oligosaccharides for the manufacture of a nutritional composition for use in preventing and/or reducing the risk of occurrence of hypercholesterolemia and/or plasma-cholesterol associated atherosclerosis later in life in a human subject by administration of the nutritional composition to the human subject early in life.

A method for preventing and/or reducing the risk of occurrence of hypercholesterolemia and/or plasma-cholesterol associated atherosclerosis later in life in a human subject by administering a nutritional composition comprising a combination of Bifidobacterium breve and non-digestible oligosaccharides early in life.